21 May 2013
Keywords: solvay, updates, progress, belgium, hiked, its, expenditures
Article | 24 February 2003
Belgium's Solvay hiked its expenditures on R&D by 22% in 2002 as itpursued Phase III trials of cilansetron, a treatment for
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 February 2003
20 May 2013
© 2013 thepharmaletter.com